Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by davgroon Jul 20, 2022 2:13am
215 Views
Post# 34836214

Fact is Stranger than Fiction

Fact is Stranger than FictionSo the Dumpster has hit a new low today during one of his psychotic episodes and posted an insinuation against management of a cannabis company (NDVA) that could be percieved as defamatory.  The company lowered its net revenue guidance for unreported 2022 Q2 and the Dumpster did what he normally does and suggested a nefarious agenda on the part of the company.  I will let you read it for yourself.  Nice to see another poster call him on it.

nedstar71- (7/19/2022 3:28:47 PM) wrote:
Duster340 wrote: in my opinion, only goes higher from here. Q2 a month away, is it possible they have a surprise in revenue to the possitve side,  under promise over deliver maybe done deliberately, i know they are frustated with the stock price just like bruce campbell is. but what better way to stir up interest in the stock
So you're suggesting that June 27th the company deliberately lied about the lower revenue guidance, in order to surprise to the upside? You can't be serious. I can assure you this company doesn't operate that way and if they did they'd have a heck of a lot more issues than lower revenue to deal with.


https://stockhouse.com/companies/bullboard?symbol=v.ndva&postid=34835295
<< Previous
Bullboard Posts
Next >>